Human health

Overview
Right now, our human health project pipeline is focused on tackling two significant health challenges of our time – antimicrobial resistance and promoting weight management and liver health in the presence of obesity.

Respiratory Infections in Cystic Fibrosis
Neem's lead candidate NX-AS-401 is a potential new treatment for chronic lung infections in patients with cystic fibrosis. It is designed to help eradicate the Pseudomonas bacteria infections that are the key cause of death for cystic fibrosis patients.

NX-AS-401 has a novel mechanism of action. As a quorum sensing inhibitor it disrupts communication between bacteria, thereby preventing them from forming the film that is crucial in protecting them from current anti-Pseudomonal antibiotics.

Infection Control in Wounds
Chronic or hard-to-heal wounds are those that fail to heal within 12 weeks. These wounds are frequently complex and management can therefore be lengthy and costly both for individuals and societies.

Unfortunately, current prevalence figures for infected hard-to-heal wounds are set to rise in coming years as more of us live longer and the effects of chronic lifestyle-related diseases such as diabetes and obesity take hold.

Control of infection in these wounds is key if the right conditions are to be created for them to heal. Neem’s candidate NX-AS-911 is a potential new treatment for this challenging situation. It disrupts communication between the Pseudomonas aeruginosa bacteria that are frequently in the wound and prevents these bacteria them from forming the biofilm layer that is crucial in protecting them from current antibiotics being used.

Liver health and weight management
Obesity, or a BMI of or more than 30kg/m2 is on the rise globally. It is a strong risk factor for liver disease that, in turn, results in both a drop in the quality of life and life expectancy.

Neem’s NX-CS-201 candidate aims to assist with weight management as a way of reducing the frequency and impact of obesity-related disease symptoms.

 

Human health

Overview
Right now, our human health project pipeline is focused on tackling two significant health challenges of our time – antimicrobial resistance and promoting weight management and liver health in the presence of obesity.

Respiratory Infections in Cystic Fibrosis
Neem's lead candidate NX-AS-401 is a potential new treatment for chronic lung infections in patients with cystic fibrosis. It is designed to help eradicate the Pseudomonas bacteria infections that are the key cause of death for cystic fibrosis patients.

NX-AS-401 has a novel mechanism of action. As a quorum sensing inhibitor it disrupts communication between bacteria, thereby preventing them from forming the film that is crucial in protecting them from current anti-Pseudomonal antibiotics.

Infection Control in Wounds
Chronic or hard-to-heal wounds are those that fail to heal within 12 weeks. These wounds are frequently complex and management can therefore be lengthy and costly both for individuals and societies.

Unfortunately, current prevalence figures for infected hard-to-heal wounds are set to rise in coming years as more of us live longer and the effects of chronic lifestyle-related diseases such as diabetes and obesity take hold.

Control of infection in these wounds is key if the right conditions are to be created for them to heal. Neem’s candidate NX-AS-911 is a potential new treatment for this challenging situation. It disrupts communication between the Pseudomonas aeruginosa bacteria that are frequently in the wound and prevents these bacteria them from forming the biofilm layer that is crucial in protecting them from current antibiotics being used.

Liver health and weight management
Obesity, or a BMI of or more than 30kg/m2 is on the rise globally. It is a strong risk factor for liver disease that, in turn, results in both a drop in the quality of life and life expectancy.

Neem’s NX-CS-201 candidate aims to assist with weight management as a way of reducing the frequency and impact of obesity-related disease symptoms.